Share on StockTwits

Investment analysts at ISI Group lowered their price target on shares of Henry Schein (NASDAQ:HSIC) from $130.00 to $127.00 in a note issued to investors on Monday. The firm currently has a “neutral” rating on the stock. ISI Group’s target price suggests a potential upside of 8.19% from the stock’s previous close.

Separately, analysts at Zacks reiterated a “neutral” rating on shares of Henry Schein in a research note on Wednesday, June 11th. They now have a $126.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Henry Schein presently has a consensus rating of “Hold” and an average target price of $115.25.

Henry Schein (NASDAQ:HSIC) traded down 1.03% during mid-day trading on Monday, hitting $116.18. 272,138 shares of the company’s stock traded hands. Henry Schein has a one year low of $100.64 and a one year high of $120.99. The stock’s 50-day moving average is $118.8 and its 200-day moving average is $117.0. The company has a market cap of $9.918 billion and a P/E ratio of 23.09.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Monday, August 4th. The company reported $1.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.33 by $0.02. The company had revenue of $2.60 billion for the quarter, compared to the consensus estimate of $2.56 billion. During the same quarter in the previous year, the company posted $1.23 earnings per share. The company’s revenue for the quarter was up 9.3% on a year-over-year basis. Analysts expect that Henry Schein will post $5.38 EPS for the current fiscal year.

Henry Schein, Inc is a provider of health care products and services to office-based practitioners. It conducts its business through two segments: healthcare distribution and technology.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.